Literature DB >> 2165386

Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas.

N Nagasue1, H Kohno, Y C Chang, A Yamanoi, T Nakamura, H Yukaya, T Hayashi.   

Abstract

During the past 8 years, estrogen receptors (ERs) in the cytosol of hepatocellular carcinoma (HCC) were assayed in 66 unselected patients without preceding treatments on whom radical hepatic resection was performed. Twenty-six patients had ERs of 0.9 to 13.4 fmol/mg protein with a mean dissociation constant of 7.8 x 10(-10) M. The remaining 40 patients had no detectable amount of the receptor. There were no substantial differences between the ER-positive and ER-negative groups in preoperative clinical and laboratory data such as sex, age, alcohol abuse, underlying liver disease, and hepatic functions. Large tumors were more common in the ER-negative group and therefore the incidence of major hepatic resection was significantly higher in this group. Histopathologic studies revealed no substantial differences between the two groups. Operative mortality rate was 11.5% in the ER-positive and 12.5% in the ER-negative group. Excluding eight operative deaths, the rate of tumor recurrence in the residual liver and long-term survival rate were identical for the two study groups. The current results may indicate that the presence or absence of ERs in human HCC does not correlate to either biologic or pathologic characteristics of this tumor, but the true role of ERs in human HCC remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165386      PMCID: PMC1358049          DOI: 10.1097/00000658-199008000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives.

Authors:  U P Steinbrecher; R Lisbona; S N Huang; S Mishkin
Journal:  Dig Dis Sci       Date:  1981-11       Impact factor: 3.199

3.  Changes in estrogen receptor levels during DES-induced hepatocarcinogenesis in the Syrian hamster fed alpha-naphthoflavone.

Authors:  S A Li; J J Li
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

4.  Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma.

Authors:  N Nagasue; Y Ogawa; H Yukaya; N Ohta; A Ito
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

5.  Estrogen receptors in hepatocellular carcinoma.

Authors:  N Nagasue; A Ito; H Yukaya; Y Ogawa
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

6.  Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue.

Authors:  S Ohnishi; T Murakami; T Moriyama; K Mitamura; M Imawari
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

7.  Induction of hepatic tumors by diethylstilbestrol alone or in synergism with n-nitrosobutylurea in castrated male WF rats.

Authors:  C Sumi; K Yokoro; R Matsushima
Journal:  J Natl Cancer Inst       Date:  1983-05       Impact factor: 13.506

8.  Hepatomas: hormone receptors and therapy.

Authors:  M A Friedman; D J Demanes; P G Hoffman
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

9.  Role of estrogens as promoters of hepatic neoplasia.

Authors:  I R Wanless; A Medline
Journal:  Lab Invest       Date:  1982-03       Impact factor: 5.662

10.  Androgen receptors in hepatocellular carcinoma and surrounding parenchyma.

Authors:  N Nagasue; A Ito; H Yukaya; Y Ogawa
Journal:  Gastroenterology       Date:  1985-09       Impact factor: 22.682

View more
  4 in total

1.  Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in HA22T cells.

Authors:  Erh-Jung Huang; Cheng-Chung Wu; Shin-Da Lee; Juen-Hau Chen; Jer-Yuh Liu; Jiunn-Liang Ko; James A Lin; Min-Chi Lu; Li-Mien Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Mol Cell Biochem       Date:  2006-04-22       Impact factor: 3.396

Review 2.  Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.

Authors:  Mamta Kalra; Jary Mayes; Senait Assefa; Anil-K Kaul; Rashmi Kaul
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 3.  Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects.

Authors:  Yao-Tsung Yeh; Chien-Wei Chang; Ren-Jie Wei; Shen-Nien Wang
Journal:  Biomed Res Int       Date:  2013-01-16       Impact factor: 3.411

4.  Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis.

Authors:  Lei Deng; Hui Yang; Junwei Tang; Zhe Lin; Aihong Yin; Yun Gao; Xuehao Wang; Runqiu Jiang; Beicheng Sun
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.